SymBio Pharmaceuticals and Eisai Company, Ltd. (ESALY.PK) to Launch Symbenda(R) in Singapore for the Treatment of Low-grade Non-Hodgkin's Lymphoma and Chronic Lymphatic Leukemia
9/7/2010 2:29:32 PM
Tokyo, Sept 7, 2010 (JCN Newswire) - SymBio Pharmaceuticals Limited and Eisai Co., Ltd. announced today that Eisai's Singapore subsidiary Eisai (Singapore) Pte. Ltd. launched bendamustine hydrochloride ("bendamustine") in Singapore under the brand name Symbenda(R) as a treatment for low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia.
comments powered by